Hyperthermic Intraperitoneal Chemotherapy Program Doctors | NYU Langone Health
Find a doctor at the Hyperthermic Intraperitoneal Chemotherapy Program at NYU Langone.
Hyperthyroidism | NYU Langone Health
NYU Langone doctors treat people with hyperthyroidism with medication, radioactive iodine, or surgery, which may control or cure the disease.
Hypertonic Saline for Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Disease
The purpose of this study is to learn more about whether nebulized hypertonic saline can help improve symptoms and clearance of mycobacteria. Hypertonic saline (7% solution) for inhalation is sometimes prescribed to patients with MAC lung infections. We also want to learn how much of a burden this treatment is for participants with MAC.
Hypertrophic Cardiomyopathy | NYU Langone Health
NYU Langone doctors are experts at managing hypertrophic cardiomyopathy (HCM), an inherited heart muscle disease.
Hypertrophic Cardiomyopathy Program | NYU Langone Health
Doctors at the Hypertrophic Cardiomyopathy Program at NYU Langone offer hypertrophic cardiomyopathy surgery and medical treatment.
Hypertrophic Cardiomyopathy Program Doctors | NYU Langone Health
Find a doctor at the Hypertrophic Cardiomyopathy Program at NYU Langone.
Hypopharyngeal Cancer | NYU Langone Health
Perlmutter Cancer Center doctors use surgery, radiation therapy, and chemotherapy to manage hypopharyngeal cancer.
Hypospadias in Children | NYU Langone Health
Urologists at Hassenfeld Children’s Hospital at NYU Langone are specialists in treating hypospadias, a congenital condition affecting boys.
Hypothyroidism | NYU Langone Health
NYU Langone endocrinologists are experts at diagnosing hypothyroidism and providing personalized care.
I-SPY 2 TRIAL -Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2
The I-SPY 2.2 protocol uses the same strategy as the I-SPY 2.0 protocol to optimize response, measuring the impact of each therapeutic regimen based on change in MRI volume as well as changes in other biomarkers.• Block A: Test the most promising novel agents without standard chemotherapy,• Targeted De-escalation: Patients who are predicted to have a complete response after Block A will proceed to surgical excision• Targeted early escalation: Patients with a poor imaging response at 3 weeks will repeat imaging at 6 weeks, and proceed to “Block B” if response is not identified.• Block B: Patients will proceed to the optimal treatment combinations (best-in-class for each subtype, based on results from I-SPY 2 and other practice changing trials)• Block C: Patients with persistent disease after Block B will proceed to AC (or AC+PD-1 for patients with TNBC), those with predicted complete response will proceed to definitive surgical resection.This approach allows evaluation of emerging new agents for their ability to achieve pCR alone or in combination with known effective agents and to optimize the sequence of therapy, minimizing toxicity and maximizing benefit. An important new tool to optimize therapy will be the use of Response Predictive Subtypes (RPS) in the I-SPY 2.2 protocol. Over the past decade, we have learned about better ways to classify tumors in order to best predict response to the kinds of agents that are being used in treatment today. All patients in the I-SPY 2.2 protocol will be classified usingthe standard receptor subtyping as well as new molecular profiles that allow us to generate an RPS for each patient. In summary, the I-SPY 2.2 protocol improvements include a combination of better tumor classification and the use of sequential regimens that will enable all patients in the trial to achieve the best response with the least toxicity.